399 MOLECULAR CHARACTERIZATION OF RESPONSE TO ETROLIZUMAB AND ANTI-TNF REVEALS TREATMENT REFRACTORY ULCERATIVE COLITIS IS ASSOCIATED WITH ABUNDANCE OF RESIDUAL NEUTROPHIL SUBSETS AND ACTIVE FIBROBLAST POPULATIONS.

MLA

Eshghi, Shadi, et al. “399 Molecular Characterization of Response to Etrolizumab and Anti-Tnf Reveals Treatment Refractory Ulcerative Colitis Is Associated with Abundance of Residual Neutrophil Subsets and Active Fibroblast Populations.” Gastroenterology (00165085), vol. 166, no. 5, May 2024, p. S-92. EBSCOhost, https://doi.org/10.1016/S0016-5085(24)00707-8.

APA

Eshghi, S., Gubatan, J. M., Mazrooei, P., Quintanilla, L., Nguyen, A., Au-Yeung, A., Holman, D., Schiffman, C., O’Gorman, W., Takahashi, C., Keir, M., Rogalla, S., Hackney, J. A., & McBride, J. M. (2024). 399 Molecular Characterization of Response to Etrolizumab and Anti-Tnf Reveals Treatment Refractory Ulcerative Colitis Is Associated with Abundance of Residual Neutrophil Subsets and Active Fibroblast Populations. Gastroenterology (00165085), 166(5), S-92. https://doi.org/10.1016/S0016-5085(24)00707-8

Chicago

Eshghi, Shadi, John Mark Gubatan, Parisa Mazrooei, Luis Quintanilla, Allen Nguyen, Amelia Au-Yeung, Derek Holman, et al. 2024. “399 Molecular Characterization of Response to Etrolizumab and Anti-Tnf Reveals Treatment Refractory Ulcerative Colitis Is Associated with Abundance of Residual Neutrophil Subsets and Active Fibroblast Populations.” Gastroenterology (00165085) 166 (5): S-92. doi:10.1016/S0016-5085(24)00707-8.